Stacy Lindborg

Very stable and unfortunate, you know, kind of picture that we're seeing over time.

It's a chronic, it's one of the cancers that we really have seen.

We've seen progress in the later treatment phases, but not in frontline.

And it is, it's time.

It's really needed.

We intend to transform the standard of care in frontline ovarian cancer.

And it's very clear if we replicate the findings from phase two, that will happen.

I mean, extending, so the five-year survival rate is less than 40%.

And so if you're able to show that the median extension in this trial is 13 months, I mean, in that context, it's very, very critical.

So the best chance you have at a cure is right when you're newly diagnosed, right?

Hitting the earliest time point that you're aware that the cancer is there.

And

You know, this is a place where Immunon is really different from if you look at the standard development path for, and I'll just stay with ovarian cancer for now, you know, it is somewhat easier and maybe a more likely to succeed plan to go after a following, you know, second or third line, or to even go in the maintenance period.

And when you look at those protocols, what you're usually requiring is that the patient has responded to the frontline treatment.

So we know that there is a percentage of women that will not respond to chemotherapy and therefore they would not contribute to learning about a product.

They would unfortunately are just going to have worse outcomes.

When you're studying frontline, you're getting everybody.

You don't know who's going to respond.

It is a riskier proposition and it's a harder space.

This is what I'm learning from gynecological oncologist.